Planned research and new guidances included in the reauthorization of the US FDA’s biosimilar user fee program should help answer several lingering interchangeability and biosimilar development questions.
One of the demonstration projects in the BsUFA III regulatory science program will “investigate and evaluate the data and information, including real-world evidence, needed to meet the safety standards for determining interchangeability,” according to the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?